Ad26.COV2-S vector-based vaccine protected against infection with SARS-Cov-2, in a pre-clinical study which is published in Nature.- Johnson & Johnson
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest